Neurocrine Biosciences (NBIX) stock experienced a significant decline of 5.65% during intraday trading on Thursday. The sharp drop occurred shortly after the market opened, reflecting heightened selling pressure.

The downward movement appears to be driven by a wave of analyst actions, with several major firms lowering their price targets for the company. H.C. Wainwright reduced its target to $192 from $198, BofA cut its target to $190 from $195, Morgan Stanley trimmed its target to $173 from $175, RBC lowered its target to $177 from $180, and BMO decreased its target to $140 from $147. While most firms maintained positive ratings such as Buy or Outperform, the collective reduction in price targets suggests a more cautious outlook on the stock's near-term valuation.

This series of analyst revisions indicates a shift in sentiment that likely contributed to the stock's decline as investors reassessed their positions based on the updated expectations from Wall Street research firms.